Janssen

Company

Also known as: Janssen

Related News

LigaChem Accelerates ADC Pipeline Amid Losses, Lonza Expands Bioconjugate Capabilities

Apr 08, 2026

LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.

Zanubrutinib Shows Superior Efficacy and Persistence Over Other BTK Inhibitors in CLL and B-Cell Lymphomas

Mar 11, 2026

Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.